{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:15:22Z","timestamp":1794568522777,"version":"4.9.1"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Bioeng"],"DOI":"10.1038\/s44222-026-00444-4","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:03:15Z","timestamp":1781010195000},"page":"778-792","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multi-objective antibody design and optimization using machine learning"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-117X","authenticated-orcid":false,"given":"Yun-Huai","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9184-8610","authenticated-orcid":false,"given":"Chloe N.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9350-5232","authenticated-orcid":false,"given":"Ece","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5026-5133","authenticated-orcid":false,"given":"Yunxuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3220-007X","authenticated-orcid":false,"given":"Peter M.","family":"Tessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"444_CR1","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","volume":"40","author":"G Walsh","year":"2022","unstructured":"Walsh, G. & Walsh, E. Biopharmaceutical benchmarks 2022. Nat. Biotechnol. 40, 1722\u20131760 (2022).","journal-title":"Nat. Biotechnol."},{"key":"444_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","volume":"27","author":"R-M Lu","year":"2020","unstructured":"Lu, R.-M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1 (2020).","journal-title":"J. Biomed. Sci."},{"key":"444_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nbt0697-553","volume":"15","author":"ET Boder","year":"1997","unstructured":"Boder, E. T. & Wittrup, K. D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553\u2013557 (1997).","journal-title":"Nat. Biotechnol."},{"key":"444_CR4","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1126\/science.4001944","volume":"228","author":"GP Smith","year":"1985","unstructured":"Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315\u20131317 (1985).","journal-title":"Science"},{"key":"444_CR5","unstructured":"Strohl, W. R. & Strohl, L. M. Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry (Woodhead Publishing, 2012)."},{"key":"444_CR6","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1073\/pnas.94.10.4937","volume":"94","author":"J Hanes","year":"1997","unstructured":"Hanes, J. & Pl\u00fcckthun, A. In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl Acad. Sci. USA 94, 4937\u20134942 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"444_CR7","doi-asserted-by":"publisher","first-page":"9637","DOI":"10.1073\/pnas.0603653103","volume":"103","author":"M Ho","year":"2006","unstructured":"Ho, M., Nagata, S. & Pastan, I. Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc. Natl Acad. Sci. USA 103, 9637\u20139642 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"444_CR8","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3390\/ijms24065994","volume":"24","author":"B Jin","year":"2023","unstructured":"Jin, B., Odongo, S., Radwanska, M. & Magez, S. NANOBODIES\u00ae: a review of diagnostic and therapeutic applications. Int. J. Mol. Sci. 24, 5994 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"444_CR9","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1158\/0008-5472.CAN-19-2295","volume":"80","author":"I Nessler","year":"2020","unstructured":"Nessler, I. et al. Increased tumor penetration of single-domain antibody-drug conjugates improves in vivo efficacy in prostate cancer models. Cancer Res. 80, 1268\u20131278 (2020).","journal-title":"Cancer Res."},{"key":"444_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully, M. et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N. Engl. J. Med. 380, 335\u2013346 (2019).","journal-title":"N. Engl. J. Med."},{"key":"444_CR11","doi-asserted-by":"publisher","first-page":"e1514","DOI":"10.1002\/onco.13817","volume":"26","author":"KP Papadopoulos","year":"2021","unstructured":"Papadopoulos, K. P. et al. First-in-human phase I study of envafolimab, a novel subcutaneous single-domain anti-PD-L1 antibody, in patients with advanced solid tumors. Oncologist 26, e1514\u2013e1525 (2021).","journal-title":"Oncologist"},{"key":"444_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23152-6","volume":"12","author":"S Oyama","year":"2022","unstructured":"Oyama, S. et al. A novel anti-TNF-\u03b1 drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis. Sci. Rep. 12, 18102 (2022).","journal-title":"Sci. Rep."},{"key":"444_CR13","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N. Engl. J. Med. 389, 2039\u20132051 (2023).","journal-title":"N. Engl. J. Med."},{"key":"444_CR14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974\u2013977 (2008).","journal-title":"Science"},{"key":"444_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde, L. E. et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 23, 1055\u20131065 (2022).","journal-title":"Lancet Oncol."},{"key":"444_CR16","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387, 2220\u20132231 (2022).","journal-title":"N. Engl. J. Med."},{"key":"444_CR17","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont, C. et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J. Clin. Oncol. 41, 2238\u20132247 (2023).","journal-title":"J. Clin. Oncol."},{"key":"444_CR18","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A. et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387, 2232\u20132244 (2022).","journal-title":"N. Engl. J. Med."},{"key":"444_CR19","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin, A. M. et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat. Med. 29, 2259\u20132267 (2023).","journal-title":"Nat. Med."},{"key":"444_CR20","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 1721\u20131723 (2022).","journal-title":"N. Engl. J. Med."},{"key":"444_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein, C., Brinkmann, U., Reichert, J. M. & Kontermann, R. E. The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug Discov. 23, 301\u2013319 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"444_CR22","first-page":"45","volume":"4","author":"B Wang","year":"2021","unstructured":"Wang, B., Gallolu Kankanamalage, S., Dong, J. & Liu, Y. Optimization of therapeutic antibodies. Antib. Ther. 4, 45\u201354 (2021).","journal-title":"Antib. Ther."},{"key":"444_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41551-023-01074-6","volume":"8","author":"EK Makowski","year":"2023","unstructured":"Makowski, E. K. et al. Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning. Nat. Biomed. Eng. 8, 45\u201356 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"444_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2115200","volume":"14","author":"AAR Teixeira","year":"2022","unstructured":"Teixeira, A. A. R. et al. Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs. mAbs 14, 2115200 (2022).","journal-title":"mAbs"},{"key":"444_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1980942","volume":"13","author":"A Azevedo Reis Teixeira","year":"2021","unstructured":"Azevedo Reis Teixeira, A. et al. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries. mAbs 13, 1980942 (2021).","journal-title":"mAbs"},{"key":"444_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jmb.2017.11.008","volume":"430","author":"RL Kelly","year":"2018","unstructured":"Kelly, R. L., Le, D., Zhao, J. & Wittrup, K. D. Reduction of nonspecificity motifs in synthetic antibody libraries. J. Mol. Biol. 430, 119\u2013130 (2018).","journal-title":"J. Mol. Biol."},{"key":"444_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2516676","volume":"17","author":"MF Erasmus","year":"2025","unstructured":"Erasmus, M. F. et al. Developing drug-like single-domain antibodies (VHH) from in vitro libraries. mAbs 17, 2516676 (2025).","journal-title":"mAbs"},{"key":"444_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2213793","volume":"15","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. Evolution of phage display libraries for therapeutic antibody discovery. mAbs 15, 2213793 (2023).","journal-title":"mAbs"},{"key":"444_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/19420862.2019.1571879","volume":"11","author":"P Valadon","year":"2019","unstructured":"Valadon, P. et al. ALTHEA Gold LibrariesTM: antibody libraries for therapeutic antibody discovery. mAbs 11, 516\u2013531 (2019).","journal-title":"mAbs"},{"key":"444_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/pro.70090","volume":"34","author":"G Pang","year":"2025","unstructured":"Pang, G. et al. A synthetic heavy chain variable domain antibody library (VHL) provides highly functional antibodies with favorable developability. Protein Sci. 34, e70090 (2025).","journal-title":"Protein Sci."},{"key":"444_CR31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/protein\/gzt047","volume":"26","author":"Y Xu","year":"2013","unstructured":"Xu, Y. et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng. Des. Sel. 26, 663\u2013670 (2013).","journal-title":"Protein Eng. Des. Sel."},{"key":"444_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.abb.2012.04.022","volume":"526","author":"MW Traxlmayr","year":"2012","unstructured":"Traxlmayr, M. W. & Obinger, C. Directed evolution of proteins for increased stability and expression using yeast display. Arch. Biochem. Biophys. 526, 174\u2013180 (2012).","journal-title":"Arch. Biochem. Biophys."},{"key":"444_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31457-3","volume":"13","author":"EK Makowski","year":"2022","unstructured":"Makowski, E. K. et al. Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space. Nat. Commun. 13, 3788 (2022).","journal-title":"Nat. Commun."},{"key":"444_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1829335","volume":"12","author":"MR Dyson","year":"2020","unstructured":"Dyson, M. R. et al. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. mAbs 12, 1829335 (2020).","journal-title":"mAbs"},{"key":"444_CR35","doi-asserted-by":"publisher","first-page":"1170081","DOI":"10.3389\/fbioe.2023.1170081","volume":"11","author":"O Huhtinen","year":"2023","unstructured":"Huhtinen, O., Salbo, R., Lamminm\u00e4ki, U. & Prince, S. Selection of biophysically favorable antibody variants using a modified Flp-In CHO mammalian display platform. Front. Bioeng. Biotechnol. 11, 1170081 (2023).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"444_CR36","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/nbt1336","volume":"25","author":"SM Lippow","year":"2007","unstructured":"Lippow, S. M., Wittrup, K. D. & Tidor, B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat. Biotechnol. 25, 1171\u20131176 (2007).","journal-title":"Nat. Biotechnol."},{"key":"444_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007207","volume":"15","author":"S Warszawski","year":"2019","unstructured":"Warszawski, S. et al. Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces. PLoS Comput. Biol. 15, e1007207 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"444_CR38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jmb.2014.09.026","volume":"427","author":"P Sormanni","year":"2015","unstructured":"Sormanni, P., Aprile, F. A. & Vendruscolo, M. The CamSol method of rational design of protein mutants with enhanced solubility. J. Mol. Biol. 427, 478\u2013490 (2015).","journal-title":"J. Mol. Biol."},{"key":"444_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2511220","volume":"17","author":"FA Dreyer","year":"2025","unstructured":"Dreyer, F. A. et al. Computational design of therapeutic antibodies with improved developability: efficient traversal of binder landscapes and rescue of escape mutations. mAbs 17, 2511220 (2025).","journal-title":"mAbs"},{"key":"444_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.add2187","volume":"378","author":"J Dauparas","year":"2022","unstructured":"Dauparas, J. et al. Robust deep learning\u2013based protein sequence design using ProteinMPNN. Science 378, 49\u201356 (2022).","journal-title":"Science"},{"key":"444_CR41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41587-023-01763-2","volume":"42","author":"BL Hie","year":"2024","unstructured":"Hie, B. L. et al. Efficient evolution of human antibodies from general protein language models. Nat. Biotechnol. 42, 275\u2013283 (2024).","journal-title":"Nat. Biotechnol."},{"key":"444_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1126\/science.adk8946","volume":"385","author":"VR Shanker","year":"2024","unstructured":"Shanker, V. R., Bruun, T. U. J., Hie, B. L. & Kim, P. S. Unsupervised evolution of protein and antibody complexes with a structure-informed language model. Science 385, 46\u201353 (2024).","journal-title":"Science"},{"key":"444_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s42256-023-00778-3","volume":"6","author":"A Ramon","year":"2024","unstructured":"Ramon, A. et al. Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV. Nat. Mach. Intell. 6, 74\u201391 (2024).","journal-title":"Nat. Mach. Intell."},{"key":"444_CR44","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41551-021-00699-9","volume":"5","author":"DM Mason","year":"2021","unstructured":"Mason, D. M. et al. Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning. Nat. Biomed. Eng. 5, 600\u2013612 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"444_CR45","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449\u2013W454 (2020).","journal-title":"Nucleic Acids Res."},{"key":"444_CR46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.bej.2018.06.003","volume":"137","author":"LA Rabia","year":"2018","unstructured":"Rabia, L. A., Desai, A. A., Jhajj, H. S. & Tessier, P. M. Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility. Biochem. Eng. J. 137, 365\u2013374 (2018).","journal-title":"Biochem. Eng. J."},{"key":"444_CR47","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41592-019-0598-1","volume":"16","author":"EC Alley","year":"2019","unstructured":"Alley, E. C., Khimulya, G., Biswas, S., AlQuraishi, M. & Church, G. M. Unified rational protein engineering with sequence-based deep representation learning. Nat. Methods 16, 1315\u20131322 (2019).","journal-title":"Nat. Methods"},{"key":"444_CR48","doi-asserted-by":"crossref","unstructured":"Ministro, J., Manuel, A. M. & Goncalves, J. in Current Applications of Pharmaceutical Biotechnology, Vol. 171 (eds Silva, A. C. et al.) 55\u201386 (Springer, 2019).","DOI":"10.1007\/10_2019_116"},{"key":"444_CR49","doi-asserted-by":"crossref","unstructured":"Steinitz, M. Human Monoclonal Antibodies: Methods and Protocols (Humana Press, 2014).","DOI":"10.1007\/978-1-62703-586-6"},{"key":"444_CR50","doi-asserted-by":"publisher","unstructured":"Bachas, S. et al. Antibody optimization enabled by artificial intelligence predictions of binding affinity and naturalness. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.08.16.504181 (2022).","DOI":"10.1101\/2022.08.16.504181"},{"key":"444_CR51","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. RoBERTa: a robustly optimized BERT pretraining approach. Preprint at https:\/\/doi.org\/10.48550\/arXiv.1907.11692 (2019).","DOI":"10.48550\/arXiv.1907.11692"},{"key":"444_CR52","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.4049\/jimmunol.1800708","volume":"201","author":"A Kovaltsuk","year":"2018","unstructured":"Kovaltsuk, A. et al. Observed Antibody Space: a resource for data mining next-generation sequencing of antibody repertoires. J. Immunol. 201, 2502\u20132509 (2018).","journal-title":"J. Immunol."},{"key":"444_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/pro.4205","volume":"31","author":"TH Olsen","year":"2022","unstructured":"Olsen, T. H., Boyles, F. & Deane, C. M. Observed Antibody Space: a diverse database of cleaned, annotated, and translated unpaired and paired antibody sequences. Protein Sci. 31, 141\u2013146 (2022).","journal-title":"Protein Sci."},{"key":"444_CR54","doi-asserted-by":"publisher","first-page":"2020203","DOI":"10.1080\/19420862.2021.2020203","volume":"14","author":"D Prihoda","year":"2022","unstructured":"Prihoda, D. et al. BioPhi: a platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning. mAbs 14, 2020203 (2022).","journal-title":"mAbs"},{"key":"444_CR55","doi-asserted-by":"publisher","first-page":"2434121","DOI":"10.1080\/19420862.2024.2434121","volume":"16","author":"L Chinery","year":"2024","unstructured":"Chinery, L., Jeliazkov, J. R. & Deane, C. M. Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains. mAbs 16, 2434121 (2024).","journal-title":"mAbs"},{"key":"444_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41551-023-01079-1","volume":"8","author":"A Tennenhouse","year":"2023","unstructured":"Tennenhouse, A. et al. Computational optimization of antibody humanness and stability by systematic energy-based ranking. Nat. Biomed. Eng. 8, 30\u201344 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"444_CR57","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/ijc.1523","volume":"94","author":"G Pavlinkova","year":"2001","unstructured":"Pavlinkova, G. et al. Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs. Int. J. Cancer 94, 717\u2013726 (2001).","journal-title":"Int. J. Cancer"},{"key":"444_CR58","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.molimm.2006.09.029","volume":"44","author":"GA Lazar","year":"2007","unstructured":"Lazar, G. A., Desjarlais, J. R., Jacinto, J., Karki, S. & Hammond, P. W. A molecular immunology approach to antibody humanization and functional optimization. Mol. Immunol. 44, 1986\u20131998 (2007).","journal-title":"Mol. Immunol."},{"key":"444_CR59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/02648725.2013.801235","volume":"29","author":"Y Safdari","year":"2013","unstructured":"Safdari, Y., Farajnia, S., Asgharzadeh, M. & Khalili, M. Antibody humanization methods - a review and update. Biotechnol. Genet. Eng. Rev. 29, 175\u2013186 (2013).","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"444_CR60","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1093\/bioinformatics\/btab434","volume":"37","author":"C Marks","year":"2021","unstructured":"Marks, C., Hummer, A. M., Chin, M. & Deane, C. M. Humanization of antibodies using a machine learning approach on large-scale repertoire data. Bioinformatics 37, 4041\u20134047 (2021).","journal-title":"Bioinformatics"},{"key":"444_CR61","doi-asserted-by":"publisher","first-page":"740","DOI":"10.4161\/mabs.22066","volume":"4","author":"V Filipe","year":"2012","unstructured":"Filipe, V. et al. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. mAbs 4, 740\u2013752 (2012).","journal-title":"mAbs"},{"key":"444_CR62","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","volume":"38","author":"CT Harris","year":"2024","unstructured":"Harris, C. T. & Cohen, S. Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies. BioDrugs 38, 205\u2013226 (2024).","journal-title":"BioDrugs"},{"key":"444_CR63","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1021\/acs.molpharmaceut.1c00280","volume":"18","author":"CG Starr","year":"2021","unstructured":"Starr, C. G. et al. Ultradilute measurements of self-association for the identification of antibodies with favorable high-concentration solution properties. Mol. Pharm. 18, 2744\u20132753 (2021).","journal-title":"Mol. Pharm."},{"key":"444_CR64","doi-asserted-by":"publisher","first-page":"1951426","DOI":"10.1080\/19420862.2021.1951426","volume":"13","author":"EK Makowski","year":"2021","unstructured":"Makowski, E. K., Wu, L., Desai, A. A. & Tessier, P. M. Highly sensitive detection of antibody nonspecific interactions using flow cytometry. mAbs 13, 1951426 (2021).","journal-title":"mAbs"},{"key":"444_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85274-7","volume":"11","author":"K Saka","year":"2021","unstructured":"Saka, K. et al. Antibody design using LSTM based deep generative model from phage display library for affinity maturation. Sci. Rep. 11, 5852 (2021).","journal-title":"Sci. Rep."},{"key":"444_CR66","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.xphs.2021.11.008","volume":"111","author":"W Jiskoot","year":"2022","unstructured":"Jiskoot, W., Hawe, A., Menzen, T., Volkin, D. B. & Crommelin, D. J. A. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: quo vadis? J. Pharm. Sci. 111, 861\u2013867 (2022).","journal-title":"J. Pharm. Sci."},{"key":"444_CR67","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/cpt.3150","volume":"115","author":"JD Davis","year":"2024","unstructured":"Davis, J. D. et al. Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development. Clin. Pharmacol. Ther. 115, 422\u2013439 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"key":"444_CR68","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.biochi.2020.08.019","volume":"177","author":"H Ma","year":"2020","unstructured":"Ma, H., \u00d3\u2019F\u00e1g\u00e1in, C. & O\u2019Kennedy, R. Antibody stability: a key to performance - analysis, influences and improvement. Biochimie 177, 213\u2013225 (2020).","journal-title":"Biochimie"},{"key":"444_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37668-6","volume":"14","author":"A Rosace","year":"2023","unstructured":"Rosace, A. et al. Automated optimisation of solubility and conformational stability of antibodies and proteins. Nat. Commun. 14, 1937 (2023).","journal-title":"Nat. Commun."},{"key":"444_CR70","doi-asserted-by":"publisher","first-page":"W382","DOI":"10.1093\/nar\/gki387","volume":"33","author":"J Schymkowitz","year":"2005","unstructured":"Schymkowitz, J. et al. The FoldX web server: an online force field. Nucleic Acids Res. 33, W382\u2013W388 (2005).","journal-title":"Nucleic Acids Res."},{"key":"444_CR71","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/B978-0-12-381270-4.00019-6","volume":"487","author":"A Leaver-Fay","year":"2011","unstructured":"Leaver-Fay, A. et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 487, 545\u2013574 (2011).","journal-title":"Methods Enzymol."},{"key":"444_CR72","doi-asserted-by":"publisher","unstructured":"Dreyer, F. A., Cutting, D., Schneider, C., Kenlay, H. & Deane, C. M. Inverse folding for antibody sequence design using deep learning. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2310.19513 (2023).","DOI":"10.48550\/arXiv.2310.19513"},{"key":"444_CR73","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1073\/pnas.1810576116","volume":"116","author":"MIJ Raybould","year":"2019","unstructured":"Raybould, M. I. J. et al. Five computational developability guidelines for therapeutic antibody profiling. Proc. Natl Acad. Sci. USA 116, 4025\u20134030 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"444_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abp9540","volume":"8","author":"M Aguilar Rangel","year":"2022","unstructured":"Aguilar Rangel, M. et al. Fragment-based computational design of antibodies targeting structured epitopes. Sci. Adv. 8, eabp9540 (2022).","journal-title":"Sci. Adv."},{"key":"444_CR75","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235\u2013242 (2000).","journal-title":"Nucleic Acids Res."},{"key":"444_CR76","doi-asserted-by":"publisher","first-page":"D1140","DOI":"10.1093\/nar\/gkt1043","volume":"42","author":"J Dunbar","year":"2014","unstructured":"Dunbar, J. et al. SAbDab: the structural antibody database. Nucleic Acids Res. 42, D1140\u2013D1146 (2014).","journal-title":"Nucleic Acids Res."},{"key":"444_CR77","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"444_CR78","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089\u20131100 (2023).","journal-title":"Nature"},{"key":"444_CR79","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41586-025-09721-5","volume":"649","author":"NR Bennett","year":"2026","unstructured":"Bennett, N. R. et al. Atomically accurate de novo design of antibodies with RFdiffusion. Nature 649, 183\u2013193 (2026).","journal-title":"Nature"},{"key":"444_CR80","doi-asserted-by":"publisher","unstructured":"Baek, M. et al. Efficient and accurate prediction of protein structure using RoseTTAFold2. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.05.24.542179 (2023).","DOI":"10.1101\/2023.05.24.542179"},{"key":"444_CR81","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.pharmthera.2016.04.013","volume":"169","author":"JA Douthwaite","year":"2017","unstructured":"Douthwaite, J. A., Finch, D. K., Mustelin, T. & Wilkinson, T. C. I. Development of therapeutic antibodies to G protein-coupled receptors and ion channels: opportunities, challenges and their therapeutic potential in respiratory diseases. Pharmacol. Ther. 169, 113\u2013123 (2017).","journal-title":"Pharmacol. Ther."},{"key":"444_CR82","first-page":"257","volume":"3","author":"CJ Hutchings","year":"2020","unstructured":"Hutchings, C. J. Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels. Antib. Ther. 3, 257\u2013264 (2020).","journal-title":"Antib. Ther."},{"key":"444_CR83","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40259-024-00682-1","volume":"38","author":"AD Stephens","year":"2024","unstructured":"Stephens, A. D. & Wilkinson, T. Discovery of therapeutic antibodies targeting complex multi-spanning membrane proteins. BioDrugs 38, 769\u2013794 (2024).","journal-title":"BioDrugs"},{"key":"444_CR84","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ymeth.2020.05.006","volume":"180","author":"R Dodd","year":"2020","unstructured":"Dodd, R., Schofield, D. J., Wilkinson, T. & Britton, Z. T. Generating therapeutic monoclonal antibodies to complex multi-spanning membrane targets: overcoming the antigen challenge and enabling discovery strategies. Methods 180, 111\u2013126 (2020).","journal-title":"Methods"},{"key":"444_CR85","doi-asserted-by":"publisher","unstructured":"Nabla Bio & Biswas, S. De novo design of hundreds of functional GPCR-targeting antibodies enabled by scaling test-time compute. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.05.28.656709 (2025).","DOI":"10.1101\/2025.05.28.656709"},{"key":"444_CR86","doi-asserted-by":"publisher","first-page":"104025","DOI":"10.1016\/j.drudis.2024.104025","volume":"29","author":"L Wossnig","year":"2024","unstructured":"Wossnig, L., Furtmann, N., Buchanan, A., Kumar, S. & Greiff, V. Best practices for machine learning in antibody discovery and development. Drug Discov. Today 29, 104025 (2024).","journal-title":"Drug Discov. Today"},{"key":"444_CR87","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12929-025-01141-x","volume":"32","author":"R Matsunaga","year":"2025","unstructured":"Matsunaga, R. & Tsumoto, K. Accelerating antibody discovery and optimization with high-throughput experimentation and machine learning. J. Biomed. Sci. 32, 46 (2025).","journal-title":"J. Biomed. Sci."},{"key":"444_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114801","volume":"43","author":"H-T Chen","year":"2024","unstructured":"Chen, H.-T. et al. Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions. Cell Rep. 43, 114801 (2024).","journal-title":"Cell Rep."},{"key":"444_CR89","doi-asserted-by":"publisher","first-page":"baad021","DOI":"10.1093\/database\/baad021","volume":"2023","author":"MS Vald\u00e9s-Tresanco","year":"2023","unstructured":"Vald\u00e9s-Tresanco, M. S., Vald\u00e9s-Tresanco, M. E., Molina-Abad, E. & Moreno, E. NbThermo: a new thermostability database for nanobodies. Database 2023, baad021 (2023).","journal-title":"Database"},{"key":"444_CR90","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/bioinformatics\/btaa739","volume":"37","author":"MIJ Raybould","year":"2021","unstructured":"Raybould, M. I. J., Kovaltsuk, A., Marks, C. & Deane, C. M. CoV-AbDab: the coronavirus antibody database. Bioinformatics 37, 734\u2013735 (2021).","journal-title":"Bioinformatics"},{"key":"444_CR91","doi-asserted-by":"publisher","unstructured":"Liu, C. et al. AbRank: a benchmark dataset and metric-learning framework for antibody-antigen affinity ranking. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2506.17857 (2025).","DOI":"10.48550\/arXiv.2506.17857"},{"key":"444_CR92","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1073\/pnas.1616408114","volume":"114","author":"T Jain","year":"2017","unstructured":"Jain, T. et al. Biophysical properties of the clinical-stage antibody landscape. Proc. Natl Acad. Sci. USA 114, 944\u2013949 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"444_CR93","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/s41587-024-02469-9","volume":"42","author":"MF Erasmus","year":"2024","unstructured":"Erasmus, M. F. et al. AIntibody: an experimentally validated in silico antibody discovery design challenge. Nat. Biotechnol. 42, 1637\u20131642 (2024).","journal-title":"Nat. Biotechnol."},{"key":"444_CR94","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.cels.2023.12.003","volume":"15","author":"M Minot","year":"2024","unstructured":"Minot, M. & Reddy, S. T. Meta learning addresses noisy and under-labeled data in machine learning-guided antibody engineering. Cell Syst. 15, 4\u201318.e4 (2024).","journal-title":"Cell Syst."},{"key":"444_CR95","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/s42256-025-01089-5","volume":"7","author":"E Ursu","year":"2025","unstructured":"Ursu, E. et al. Training data composition determines machine learning generalization and biological rule discovery. Nat. Mach. Intell. 7, 1206\u20131219 (2025).","journal-title":"Nat. Mach. Intell."},{"key":"444_CR96","doi-asserted-by":"publisher","first-page":"D1262","DOI":"10.1093\/nar\/gkab1136","volume":"50","author":"T Manso","year":"2022","unstructured":"Manso, T. et al. IMGT\u00ae databases, related tools and web resources through three main axes of research and development. Nucleic Acids Res. 50, D1262\u2013D1272 (2022).","journal-title":"Nucleic Acids Res."},{"key":"444_CR97","doi-asserted-by":"publisher","unstructured":"Shanehsazzadeh, A. et al. Unlocking de novo antibody design with generative artificial intelligence. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.01.08.523187 (2023).","DOI":"10.1101\/2023.01.08.523187"},{"key":"444_CR98","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.ade2574","volume":"379","author":"Z Lin","year":"2023","unstructured":"Lin, Z. et al. Evolutionary-scale prediction of atomic-level protein structure with a language model. Science 379, 1123\u20131130 (2023).","journal-title":"Science"},{"key":"444_CR99","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/bioinformatics\/btu739","volume":"31","author":"BE Suzek","year":"2015","unstructured":"Suzek, B. E. et al. UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches. Bioinformatics 31, 926\u2013932 (2015).","journal-title":"Bioinformatics"},{"key":"444_CR100","doi-asserted-by":"publisher","unstructured":"Devlin, J., Chang, M.-W., Lee, K. & Toutanova, K. BERT: pre-training of deep bidirectional transformers for language understanding. Preprint at https:\/\/doi.org\/10.48550\/arXiv.1810.04805 (2018).","DOI":"10.48550\/arXiv.1810.04805"},{"key":"444_CR101","first-page":"199","volume":"7","author":"X Yu","year":"2024","unstructured":"Yu, X. et al. Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies. Antib. Ther. 7, 199\u2013208 (2024).","journal-title":"Antib. Ther."},{"key":"444_CR102","doi-asserted-by":"publisher","first-page":"7112","DOI":"10.1109\/TPAMI.2021.3095381","volume":"44","author":"A Elnaggar","year":"2022","unstructured":"Elnaggar, A. et al. ProtTrans: toward understanding the language of life through self-supervised learning. IEEE Trans. Pattern Anal. Mach. Intell. 44, 7112\u20137127 (2022).","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"key":"444_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04964-5","volume":"9","author":"M Steinegger","year":"2018","unstructured":"Steinegger, M. & S\u00f6ding, J. Clustering huge protein sequence sets in linear time. Nat. Commun. 9, 2542 (2018).","journal-title":"Nat. Commun."},{"key":"444_CR104","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41592-019-0437-4","volume":"16","author":"M Steinegger","year":"2019","unstructured":"Steinegger, M., Mirdita, M. & S\u00f6ding, J. Protein-level assembly increases protein sequence recovery from metagenomic samples manyfold. Nat. Methods 16, 603\u2013606 (2019).","journal-title":"Nat. Methods"},{"key":"444_CR105","doi-asserted-by":"publisher","first-page":"btae268","DOI":"10.1093\/bioinformatics\/btae268","volume":"40","author":"ZA Rollins","year":"2024","unstructured":"Rollins, Z. A., Widatalla, T., Waight, A., Cheng, A. C. & Metwally, E. AbLEF: antibody language ensemble fusion for thermodynamically empowered property predictions. Bioinformatics 40, btae268 (2024).","journal-title":"Bioinformatics"},{"key":"444_CR106","doi-asserted-by":"publisher","first-page":"vbac046","DOI":"10.1093\/bioadv\/vbac046","volume":"2","author":"TH Olsen","year":"2022","unstructured":"Olsen, T. H., Moal, I. H. & Deane, C. M. AbLang: an antibody language model for completing antibody sequences. Bioinform. Adv. 2, vbac046 (2022).","journal-title":"Bioinform. Adv."},{"key":"444_CR107","doi-asserted-by":"publisher","first-page":"btae618","DOI":"10.1093\/bioinformatics\/btae618","volume":"40","author":"TH Olsen","year":"2024","unstructured":"Olsen, T. H., Moal, I. H. & Deane, C. M. Addressing the antibody germline bias and its effect on language models for improved antibody design. Bioinformatics 40, btae618 (2024).","journal-title":"Bioinformatics"},{"key":"444_CR108","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cels.2023.10.001","volume":"14","author":"RW Shuai","year":"2023","unstructured":"Shuai, R. W., Ruffolo, J. A. & Gray, J. J. IgLM: Infilling language modeling for antibody sequence design. Cell Syst. 14, 979\u2013989.e4 (2023).","journal-title":"Cell Syst."},{"key":"444_CR109","unstructured":"Radford, A. et al. Language Models Are Unsupervised Multitask Learners https:\/\/cdn.openai.com\/better-language-models\/language_models_are_unsupervised_multitask_learners.pdf (2019)."},{"key":"444_CR110","doi-asserted-by":"publisher","unstructured":"Ruffolo, J. A., Gray, J. J. & Sulam, J. Deciphering antibody affinity maturation with language models and weakly supervised learning. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2112.07782 (2021).","DOI":"10.48550\/arXiv.2112.07782"},{"key":"444_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0296737","volume":"19","author":"H Wang","year":"2024","unstructured":"Wang, H., Hao, X., He, Y. & Fan, L. AbImmPred: an immunogenicity prediction method for therapeutic antibodies using antiBERTy-based sequence features. PLoS ONE 19, e0296737 (2024).","journal-title":"PLoS ONE"},{"key":"444_CR112","doi-asserted-by":"publisher","first-page":"100513","DOI":"10.1016\/j.patter.2022.100513","volume":"3","author":"J Leem","year":"2022","unstructured":"Leem, J., Mitchell, L. S., Farmery, J. H. R., Barton, J. & Galson, J. D. Deciphering the language of antibodies using self-supervised learning. Patterns 3, 100513 (2022).","journal-title":"Patterns"},{"key":"444_CR113","doi-asserted-by":"publisher","unstructured":"Hsu, C. et al. Learning inverse folding from millions of predicted structures. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.04.10.487779 (2022).","DOI":"10.1101\/2022.04.10.487779"},{"key":"444_CR114","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0969-2126(97)00260-8","volume":"5","author":"CA Orengo","year":"1997","unstructured":"Orengo, C. A. et al. CATH\u2014a hierarchic classification of protein domain structures. Structure 5, 1093\u20131108 (1997).","journal-title":"Structure"},{"key":"444_CR115","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s42003-023-04927-7","volume":"6","author":"B Abanades","year":"2023","unstructured":"Abanades, B. et al. ImmuneBuilder: deep-learning models for predicting the structures of immune proteins. Commun. Biol. 6, 575 (2023).","journal-title":"Commun. Biol."},{"key":"444_CR116","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbae202","volume":"5","author":"MH H\u00f8ie","year":"2025","unstructured":"H\u00f8ie, M. H. et al. AntiFold: improved structure-based antibody design using inverse folding. Bioinform. Adv. 5, vbae202 (2025).","journal-title":"Bioinform. Adv."},{"key":"444_CR117","doi-asserted-by":"publisher","first-page":"btae659","DOI":"10.1093\/bioinformatics\/btae659","volume":"40","author":"OM Turnbull","year":"2024","unstructured":"Turnbull, O. M., Oglic, D., Croasdale-Wood, R. & Deane, C. M. p-IgGen: a paired antibody generative language model. Bioinformatics 40, btae659 (2024).","journal-title":"Bioinformatics"},{"key":"444_CR118","unstructured":"UniProt: the universal protein knowledgebase in 2025. Nucleic Acids Res. 53, D609\u2013D617 (2025)."},{"key":"444_CR119","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"R Adams","year":"2020","unstructured":"Adams, R. et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front. Immunol. 11, 1894 (2020).","journal-title":"Front. Immunol."},{"key":"444_CR120","unstructured":"Shi, J., Baker, T., Lawson, A. D. G. & Liu, X. Obtaining an improved therapeutic ligand. WIPO patent WO2014198951A2 (2014)."},{"key":"444_CR121","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.2024.42.16_suppl.2527","volume":"42","author":"DW Rasco","year":"2024","unstructured":"Rasco, D. W. et al. Updated results of a phase 1\/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors. J. Clin. Oncol. 42, 2527\u20132527 (2024).","journal-title":"J. Clin. Oncol."},{"key":"444_CR122","unstructured":"Ofran, Y., Nimrod, G., Fischman, S. & Herman, A. Computer assisted antibody re-epitoping. WIPO patent WO2016086185A1 (2016)."},{"key":"444_CR123","doi-asserted-by":"publisher","first-page":"2451789","DOI":"10.1080\/19420862.2025.2451789","volume":"17","author":"C Chen","year":"2025","unstructured":"Chen, C., Garcia, Z., Chen, D., Liu, H. & Trelstad, P. Cost and supply considerations for antibody therapeutics. mAbs 17, 2451789 (2025).","journal-title":"mAbs"},{"key":"444_CR124","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20\u201333 (2016).","journal-title":"J. Health Econ."},{"key":"444_CR125","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s43588-025-00823-8","volume":"5","author":"AM Hummer","year":"2025","unstructured":"Hummer, A. M., Schneider, C., Chinery, L. & Deane, C. M.\u00a0Investigating the volume and diversity of data needed for generalizable antibody\u2013antigen \u0394\u0394G prediction. Nat. Comput. Sci. 5, 635\u2013647 (2025).","journal-title":"Nat. Comput. Sci."}],"container-title":["Nature Reviews Bioengineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44222-026-00444-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44222-026-00444-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44222-026-00444-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:02:00Z","timestamp":1786449720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44222-026-00444-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":125,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1038\/s44222-026-00444-4","relation":{},"ISSN":["2731-6092"],"issn-type":[{"value":"2731-6092","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"13 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.M.T. is a member of the scientific advisory boards for Nabla Bio, Aureka Biotechnologies, Dualitas Therapeutics, CelineBio and Metaphore Biotechnologies.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}